

Panacea Biotec Ltd

September 20, 2017

Ratings

Facilities	Amount (Rs. crore)	Rating ¹	Rating Action
Long term Bank Facilities	959.55 (reduced from Rs.1202.88 crore)	CARE D	Revised from CARE B+ (Single B Plus)
Short term Bank Facilities	61.97	CARE D	Revised from CARE A4 (A Four)
Total	1021.52 (Rupees One thousand twenty one crore and fifty two lakh only)		

Details of instruments/facilities in Annexure-1

Detailed Rationale & Key Rating Drivers

The revision in the ratings assigned to the bank facilities of Panacea Biotec Limited (PBL) take into account the delays in servicing of its debt obligation during FY17 (refers to the period April 1 to March 31).

Going forward, the ability of the company to improve its liquidity position and strengthen its capital structure with improvement in its profitability would remain the key rating sensitivity.

Key Rating Weaknesses

Delays in servicing of debt obligations: On account of stretched liquidity position, there were delays in repayment of debt obligations due in March 2017 by the company to various banks. The delays were however, cleared by the company in April 2017. Going forward, the ability of the company to improve its liquidity position shall remain critical.

Weak financial risk profile: During FY17, PBL reported total operating income of Rs.582.42 crore as compared to total operating income of Rs.672.46 crore in FY16, registering y-o-y decline of around 13%. The net revenues from operations have mainly decreased due to lower sale of pentavalent vaccine Easy - TT to UNICEF/PAHO, non-availability of IPV bulk leading to no sales of IPV vaccine, reduction in prices of products due to price control by NPPA, banning of irrational FDCs by DCGI and expiry of excise duty holiday period at Baddi facilities. PBILDT margin was 20.76% in FY17 (FY16: 20.53%). PBL has incurred loss before tax of Rs.83.78 crore (after considering exceptional items of Rs.37.54 crore) as against profit before tax of Rs.1.40 crore (after considering exceptional income of Rs.49.65 crore) for FY16. During the year, the exceptional items include provisioning of Rs.45.08 crore towards impairment of investments in NewRise Healthcare Pvt. Ltd. on account of sale thereof in April 2017. The overall gearing deteriorated from 10.13x as on March 31, 2016 to 22.65x as on March 31, 2017. Further in Q1FY18, PBL's Operating income was Rs 105.50 crore with negative PBILDT of Rs 6.02 crore as against income of Rs 135.22 crore with PBILDT of Rs 21.42 crore in Q1FY17. PBL registered a decline in sales in Q1FY18 of 22% over the similar period in the last financial year.

Key Rating Strengths

Experienced promoters and management team and long track record of operations: The Company has been in the pharmaceutical business since 1984 and has a long track record of operations of more than 30 years. The company is promoted by the Jain family headed by Mr Soshil Kumar Jain who has an experience of more than 50 years in the pharmaceutical industry. He is assisted by Mr Ravinder Jain, Dr Rajesh Jain and Mr Sandeep Jain in looking after the operations of the company. The senior management team of PBL comprises of well-qualified and experienced members.

Analytical approach:

Standalone

¹Complete definition of the ratings assigned are available at www.careratings.com and other CARE publications

Applicable Criteria

[Criteria on assigning Outlook to Credit Ratings](#)

[CARE's Policy on Default Recognition](#)

[CARE's methodology for manufacturing companies](#)

[Rating Methodology - Pharmaceutical Sector](#)

[Financial ratios – Non-Financial Sector](#)

[Criteria for Short Term Instruments](#)

About the Company

Panacea Biotech Limited (PBL) was incorporated in February, 1984 under the name of Panacea Drugs Private Limited (PDPL). In September 1993, it was converted into a public limited company and its name was changed to the present one. PBL is promoted by the Jain family headed by Mr. Soshil Kumar Jain and is one of the leading biotechnology companies in India involved in manufacturing of vaccines and pharmaceutical formulations. PBL has manufacturing facilities in Himachal Pradesh and Punjab for vaccines and pharmaceutical formulations complying with international regulatory standards of USFDA, UK-MHRA, and WHO-cGMP standards etc. On account of the deterioration in the financial risk profile during the period FY12-14, the company approached the CDR cell for restructuring of the debt and executed a CDR scheme in FY15. Since then, PBL continues to service its debt obligations as per the CDR terms.

Brief Financials (Rs. crore)	FY16 (A)	FY17 (A)
Total operating income	672.46	582.42
PBILDT	138.07	120.91
PAT	0.87	-86.25
Overall gearing (times)	10.13	22.65
Interest coverage (times)	1.20	1.19

A: Audited

Status of non-cooperation with previous CRA: Not Applicable

Any other information: Not Applicable

Rating History for last three years: Please refer Annexure-2

Note on complexity levels of the rated instrument: CARE has classified instruments rated by it on the basis of complexity. This classification is available at www.careratings.com. Investors/market intermediaries/regulators or others are welcome to write to care@careratings.com for any clarifications.

Analyst Contact

Name: Mr Gaurav Dixit

Tel: 011-45333235

Cell: 9717070079

Email: gaurav.dixit@careratings.com

****For detailed Rationale Report and subscription information, please contact us at www.careratings.com**

About CARE Ratings:

CARE Ratings commenced operations in April 1993 and over two decades, it has established itself as one of the leading credit rating agencies in India. CARE is registered with the Securities and Exchange Board of India (SEBI) and also recognized as an External Credit Assessment Institution (ECAI) by the Reserve Bank of India (RBI). CARE Ratings is proud of its rightful place in the Indian capital market built around investor confidence. CARE Ratings provides the entire spectrum of credit rating that helps the corporates to raise capital for their various requirements and assists the investors to form an informed investment decision based on the credit risk and their own risk-return expectations. Our rating and grading service offerings leverage our domain and analytical expertise backed by the methodologies congruent with the international best practices.

Disclaimer

CARE's ratings are opinions on credit quality and are not recommendations to sanction, renew, disburse or recall the concerned bank facilities or to buy, sell or hold any security. CARE has based its ratings/outlooks on information obtained from sources believed by it to be accurate and reliable. CARE does not, however, guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE have paid a credit rating fee, based on the amount and type of bank facilities/instruments.

In case of partnership/proprietary concerns, the rating /outlook assigned by CARE is based on the capital deployed by the partners/proprietor and the financial strength of the firm at present. The rating/outlook may undergo change in case of withdrawal of capital or the unsecured loans brought in by the partners/proprietor in addition to the financial performance and other relevant factors.

Annexure-1: Details of Instruments/Facilities

Name of the Instrument	Date of Issuance	Coupon Rate	Maturity Date	Size of the Issue (Rs. crore)	Rating assigned along with Rating Outlook
Fund-based-Long Term	-	-	-	959.55	CARE D
Non-fund-based-Short Term	-	-	-	61.97	CARE D

Annexure-2: Rating History of last three years

Sr. No.	Name of the Instrument/Bank Facilities	Current Ratings			Rating history			
		Type	Amount Outstanding (Rs. crore)	Rating	Date(s) & Rating(s) assigned in 2017-2018	Date(s) & Rating(s) assigned in 2016-2017	Date(s) & Rating(s) assigned in 2015-2016	Date(s) & Rating(s) assigned in 2014-2015
1.	Fund-based-Long Term	LT	959.55	CARE D	-	1)CARE B+ (12-Aug-16)	1)CARE B- (31-Mar-16) 2)CARE D (23-Apr-15)	-
2.	Non-fund-based-Short Term	ST	61.97	CARE D	-	1)CARE A4 (12-Aug-16)	1)CARE A4 (31-Mar-16) 2)CARE D / CARE D (23-Apr-15)	-

CONTACT**Head Office Mumbai**

Ms. Meenal Sikchi
 Cell: + 91 98190 09839
 E-mail: meenal.sikchi@careratings.com

Mr. Ankur Sachdeva
 Cell: + 91 98196 98985
 E-mail: ankur.sachdeva@careratings.com

Ms. Rashmi Narvankar
 Cell: + 91 99675 70636
 E-mail: rashmi.narvankar@careratings.com

Mr. Saikat Roy
 Cell: + 91 98209 98779
 E-mail: saikat.roy@careratings.com

CARE Ratings Limited**(Formerly known as Credit Analysis & Research Ltd.)**

Corporate Office: 4th Floor, Godrej Coliseum, Somaiya Hospital Road, Off Eastern Express Highway, Sion (East), Mumbai - 400 022
 Tel: +91-22-6754 3456 | Fax: +91-22-6754 3457 | E-mail: care@careratings.com

AHMEDABAD

Mr. Deepak Prajapati
 32, Titanium, Prahaladnagar Corporate Road,
 Satellite, Ahmedabad - 380 015
 Cell: +91-9099028864
 Tel: +91-79-4026 5656
 E-mail: deepak.prajapati@careratings.com

JAIPUR

Mr. Nikhil Soni
 304, Pashupati Akshat Heights, Plot No. D-91,
 Madho Singh Road, Near Collectorate Circle,
 Bani Park, Jaipur - 302 016.
 Cell: +91 – 95490 33222
 Tel: +91-141-402 0213 / 14
 E-mail: nikhil.soni@careratings.com

BENGALURU

Mr. V Pradeep Kumar
 Unit No. 1101-1102, 11th Floor, Prestige Meridian II,
 No. 30, M.G. Road, Bangalore - 560 001.
 Cell: +91 98407 54521
 Tel: +91-80-4115 0445, 4165 4529
 Email: pradeep.kumar@careratings.com

KOLKATA

Ms. Priti Agarwal
 3rd Floor, Prasad Chambers, (Shagun Mall Bldg.)
 10A, Shakespeare Sarani, Kolkata - 700 071.
 Cell: +91-98319 67110
 Tel: +91-33- 4018 1600
 E-mail: priti.agarwal@careratings.com

CHANDIGARH

Mr. Anand Jha
 SCF No. 54-55,
 First Floor, Phase 11,
 Sector 65, Mohali - 160062
 Chandigarh
 Cell: +91 99888 05650
 Tel: +91-172-5171 100 / 09
 Email: anand.jha@careratings.com

NEW DELHI

Ms. Swati Agrawal
 13th Floor, E-1 Block, Videocon Tower,
 Jhandewalan Extension, New Delhi - 110 055.
 Cell: +91-98117 45677
 Tel: +91-11-4533 3200
 E-mail: swati.agrawal@careratings.com

CHENNAI

Mr. V Pradeep Kumar
 Unit No. O-509/C, Spencer Plaza, 5th Floor,
 No. 769, Anna Salai, Chennai - 600 002.
 Cell: +91 98407 54521
 Tel: +91-44-2849 7812 / 0811
 Email: pradeep.kumar@careratings.com

PUNE

Mr. Pratim Banerjee
 9th Floor, Pride Kumar Senate,
 Plot No. 970, Bhamburda, Senapati Bapat Road,
 Shivaji Nagar, Pune - 411 015.
 Cell: +91-98361 07331
 Tel: +91-20- 4000 9000
 E-mail: pratim.banerjee@careratings.com

COIMBATORE

Mr. V Pradeep Kumar
 T-3, 3rd Floor, Manchester Square
 Puliakulam Road, Coimbatore - 641 037.
 Tel: +91-422-4332399 / 4502399
 Email: pradeep.kumar@careratings.com

CIN - L67190MH1993PLC071691

HYDERABAD

Mr. Ramesh Bob
 401, Ashoka Scintilla, 3-6-502, Himayat Nagar,
 Hyderabad - 500 029.
 Cell : + 91 90520 00521
 Tel: +91-40-4010 2030
 E-mail: ramesh.bob@careratings.com